PDF Cover

Avapritinib Market

The market for Avapritinib was estimated at $516 million in 2024; it is anticipated to increase to $833 million by 2030, with projections indicating growth to around $1.24 billion by 2035.

Report ID:DS1802158
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Avapritinib
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Avapritinib Market Outlook

Revenue, 2024

$516M

Forecast, 2034

$1.15B

CAGR, 2025 - 2034

8.3%

The Avapritinib industry revenue is expected to be around $558.8 million in 2025 and expected to showcase growth with 8.3% CAGR between 2025 and 2034. Building on this momentum, the avapritinib market continues to gain strategic importance within the precision oncology landscape due to its role in addressing rare and genetically defined cancers. Market growth is being supported by increasing adoption of targeted therapies, greater utilization of molecular diagnostic testing, and expanding awareness of personalized treatment approaches among healthcare providers. The growing emphasis on biomarker-driven treatment selection is improving patient identification and supporting more effective clinical outcomes. In addition, ongoing research initiatives, enhanced access to genomic profiling technologies, and increasing investments in rare disease therapeutics are reinforcing the market’s relevance. As healthcare systems continue to prioritize precision medicine, avapritinib remains an important component of advanced oncology treatment strategies.

Avapritinib is a targeted therapy designed to inhibit specific genetic mutations associated with certain rare cancers and hematologic disorders. Its key features include high selectivity for target mutations, oral administration, and its role in precision medicine treatment pathways. Major applications are centered on the treatment of gastrointestinal stromal tumors with specific genetic alterations and advanced systemic mastocytosis, where targeted intervention offers improved disease management opportunities. The therapy is primarily utilized in oncology centers, specialty hospitals, and academic research institutions that employ molecular testing to guide treatment decisions. Recent trends driving demand include the growing adoption of companion diagnostics, expansion of personalized oncology programs, and increasing clinical focus on rare cancer subtypes. Furthermore, advancements in genomic sequencing technologies, rising physician awareness of mutation-driven therapies, and continued research into novel indications are supporting broader utilization. The increasing integration of precision oncology into routine clinical practice is expected to further strengthen demand for avapritinib across specialized therapeutic settings.

Avapritinib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Avapritinib Market Outlook

Market Key Insights

  • The Avapritinib market is projected to grow from $516.0 million in 2024 to $1.15 billion in 2034. This represents a CAGR of 8.3%, reflecting rising demand across Oncological Treatment, Gastrointestinal Stromal Tumors Treatment, and Systemic Mastocytosis Treatment.

  • Blueprint Medicines Corporation, Pfizer Inc, Novartis AG are among the leading players in this market, shaping its competitive landscape.

  • U.S. and UK are the top markets within the Avapritinib market and are expected to observe the growth CAGR of 6.1% to 8.7% between 2024 and 2030.

  • Emerging markets including Brazil, Turkey and South Africa are expected to observe highest growth with CAGR ranging between 8.0% to 10.4%.

  • Transition like Transition from Broad Spectrum Oncology Treatments to Precision Medicine is expected to add $75 million to the Avapritinib market growth by 2030.

  • The Avapritinib market is set to add $629 million between 2024 and 2034, with manufacturer targeting Systemic Mastocytosis & Other Rare Cancers Application projected to gain a larger market share.

  • With

    rise in gastrointestinal stromal tumors, and

    Intensified Research and Development Activities, Avapritinib market to expand 122% between 2024 and 2034.

avapritinib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Avapritinib - Country Share Analysis

Opportunities in the Avapritinib

A major opportunity for the avapritinib market lies in the expansion of rare cancer treatment programs within specialized oncology centers. Healthcare providers are increasingly establishing dedicated units focused on mutation-driven cancers, supported by advanced molecular diagnostic capabilities. This trend is improving patient identification and accelerating access to targeted therapies. Strategic collaborations between pharmaceutical companies, research institutions, and cancer centers are also enhancing awareness of rare disease treatment pathways. The oncological treatment application segment is expected to benefit the most as precision medicine adoption continues to expand across specialized cancer care networks.

Growth Opportunities in North America and Asia Pacific

North America represents the largest and most established market for avapritinib, supported by advanced oncology infrastructure, widespread adoption of precision medicine, and strong utilization of genomic testing. Key market drivers include increasing awareness of rare cancers, expanding access to molecular diagnostics, and favorable support for personalized treatment approaches. Significant opportunities exist in the expansion of biomarker-driven oncology programs, rare disease treatment networks, and academic research collaborations focused on targeted therapies. The United States remains the primary contributor to regional demand due to its concentration of specialty cancer centers and high adoption of innovative oncology treatments. Competition is characterized by the presence of leading pharmaceutical companies developing targeted cancer therapies for genetically defined patient populations. Market participants are investing in physician education, patient identification initiatives, and strategic partnerships with diagnostic providers. Continued advancements in genomic profiling and growing integration of precision oncology into routine clinical practice are expected to strengthen avapritinib adoption across North America.
Asia Pacific is emerging as a high-potential region for the avapritinib market, driven by expanding healthcare expenditure, increasing cancer awareness, and growing investments in precision medicine infrastructure. Countries such as China, Japan, South Korea, and Australia are strengthening genomic testing capabilities and improving access to advanced oncology treatments. Major opportunities are linked to the expansion of molecular diagnostic services, rising adoption of personalized medicine, and the development of specialized oncology centers focused on rare cancers. Competition is intensifying as multinational pharmaceutical companies collaborate with regional healthcare providers and research institutions to improve market penetration. Government initiatives supporting cancer screening and precision healthcare are further encouraging demand. The region’s large patient population, improving diagnostic accessibility, and growing focus on targeted therapies create favorable conditions for long-term market growth. As precision oncology programs continue to mature, avapritinib is expected to gain stronger adoption across key Asia Pacific healthcare markets.

Market Dynamics and Supply Chain

01

Driver: Expanding Precision Oncology Adoption and Rising Utilization of Genomic Testing

The avapritinib market is also being strongly supported by the growing adoption of precision oncology and the increasing use of genomic testing in cancer care. Precision oncology programs are also encouraging clinicians to select therapies based on specific genetic alterations, creating greater demand for targeted treatments designed for mutation-defined patient populations. Separately, advancements in next generation sequencing and molecular diagnostic technologies are also improving the identification of actionable mutations associated with rare cancers and hematologic disorders. Healthcare institutions are also increasingly integrating comprehensive genomic profiling into routine oncology workflows, enabling earlier and more accurate patient selection. This trend is also particularly significant in rare tumor management, where targeted therapies can also offer differentiated clinical value. Together, these factors are also expanding treatment eligibility, supporting diagnosis-driven prescribing patterns, and strengthening the commercial outlook for avapritinib in specialized oncology settings.
Growing investment in rare cancer research is also emerging as a major driver for the avapritinib market. Pharmaceutical companies, academic institutions, and oncology research networks are also prioritizing therapies that address specific molecular abnormalities associated with underserved patient populations. This trend is also accelerating clinical development activities, expanding physician awareness, and improving access to innovative targeted treatment options. also advances in biomarker research are also also enabling more refined disease classification and patient stratification, supporting personalized treatment approaches. As healthcare systems place greater emphasis on rare disease management and precision medicine, demand for mutation-targeted therapies such as avapritinib continues to strengthen across specialized oncology and hematology treatment centers.
02

Restraint: Limited Eligible Patient Population Restricts Overall Commercial Market Expansion

One of the most significant restraints affecting the avapritinib market is the relatively small patient population eligible for treatment. Avapritinib is primarily prescribed for specific mutation-driven gastrointestinal stromal tumors and advanced systemic mastocytosis, which represent niche disease segments within oncology. While precision medicine improves treatment effectiveness, it also narrows the addressable market. For example, only patients identified through molecular testing as carrying relevant genetic alterations are considered suitable candidates. This limitation constrains prescription volumes, reduces large-scale revenue opportunities, and makes market expansion heavily dependent on improved diagnosis rates and broader identification of eligible patients.
03

Opportunity: Rising Precision Medicine Investments In Asia Pacific Healthcare and Growing Genomic Testing Adoption Among Gastrointestinal Stromal Tumor Patients

Asia Pacific offers a promising opportunity for the avapritinib market due to growing investments in precision medicine and oncology infrastructure. Countries such as China, Japan, and South Korea are expanding access to genomic testing, personalized cancer care, and advanced targeted therapies. Pharmaceutical companies are strengthening regional partnerships with hospitals and research organizations to improve market access and patient identification. The oncological treatment segment is expected to experience the highest growth in the region as healthcare providers increasingly adopt biomarker-based treatment strategies. Expanding healthcare expenditure and improving diagnostic capabilities further support long-term market development.
The increasing use of genomic testing among gastrointestinal stromal tumor patients presents a significant growth opportunity for avapritinib. Advances in molecular profiling technologies are enabling more accurate detection of actionable mutations, allowing clinicians to identify suitable candidates for targeted therapy. Healthcare systems are investing in precision diagnostic infrastructure, while oncology providers are integrating genetic testing into routine treatment protocols. As awareness of biomarker-driven treatment decisions increases, the gastrointestinal stromal tumors treatment application is expected to witness strong growth. This trend is particularly prominent in developed healthcare markets with expanding precision oncology programs.
04

Challenge: High Treatment Costs And Reimbursement Barriers Affect Patient Access

The premium pricing associated with targeted oncology therapies continues to challenge wider adoption of avapritinib across multiple healthcare markets. Patients, healthcare providers, and payers often face budgetary pressures when evaluating specialized treatments for rare diseases. In regions with limited reimbursement coverage, eligible patients may experience delays in therapy initiation or seek alternative treatment approaches. For instance, healthcare systems with strict cost-effectiveness assessments may limit access to high-cost targeted medicines. These reimbursement and affordability challenges influence demand patterns, slow market penetration in cost-sensitive regions, and create uncertainty around long-term revenue growth despite increasing interest in precision oncology therapies.

Supply Chain Landscape

1

API Production

Janssen PharmaceuticaSigma-Aldrich
2

Drug Formulation

Blueprint MedicinesTherachem Research Medilab
3

Regulatory Compliance

Eurofins ScientificSGS SA
4

Sales & Distribution

Johnson & JohnsonMcKesson Corporation
Avapritinib - Supply Chain

Use Cases of Avapritinib in Oncological Treatment & Gastrointestinal Stromal Tumors Treatment

Oncological Treatment : Oncological treatment represents the broadest application area for avapritinib, particularly within precision oncology programs focused on genetically defined cancers. The oral targeted therapy formulation of avapritinib is primarily used in specialty oncology centers, cancer hospitals, and academic medical institutions where molecular diagnostics guide treatment selection. Its value lies in targeting specific genetic mutations rather than relying solely on conventional treatment approaches, enabling more personalized disease management. Healthcare providers utilize avapritinib for patients whose tumors exhibit relevant molecular characteristics, improving therapeutic precision. The growing adoption of biomarker-driven treatment pathways and precision medicine initiatives continues to support its importance within modern oncology care.
Gastrointestinal Stromal Tumors Treatment : Gastrointestinal stromal tumor treatment is a key application for avapritinib, particularly among patients with specific platelet-derived growth factor receptor alpha mutations. Oral avapritinib therapy is most commonly prescribed in oncology clinics and specialized cancer treatment centers where genetic testing is routinely performed. The therapy provides a targeted approach for patients who may have limited benefit from conventional treatment options, helping improve disease control and clinical outcomes. Its unique advantage lies in its ability to selectively address mutation-driven tumor growth. Increasing availability of genomic profiling services and growing awareness of personalized cancer treatment are supporting continued demand within this specialized therapeutic segment.
Systemic Mastocytosis Treatment : Systemic mastocytosis treatment has emerged as an important application within the avapritinib market due to the need for targeted therapies addressing rare hematologic disorders. The oral formulation is widely utilized in specialty hematology and oncology centers that manage advanced forms of mast cell diseases. Avapritinib is valued for its ability to target underlying genetic drivers associated with disease progression, supporting symptom management and overall treatment effectiveness. The therapy offers advantages through a precision-based treatment approach that aligns with evolving personalized medicine practices. Rising recognition of rare diseases, improved diagnostic capabilities, and increasing referrals to specialized treatment centers are contributing to the growth of this application area.

Impact of Industry Transitions on the Avapritinib Market

As a core segment of the Pharmaceutical industry, the Avapritinib market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Broad Spectrum Oncology Treatments to Precision Medicine and Transition from Rare Disease Underdiagnosis to Genomics Driven Identification have redefined priorities across the Pharmaceutical sector, influencing how the Avapritinib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Broad Spectrum Oncology Treatments to Precision Medicine

The avapritinib market reflects the broader transition of the oncology industry from generalized cancer treatments toward precision medicine approaches. Healthcare providers are increasingly utilizing molecular diagnostics and biomarker testing to match therapies with specific genetic profiles, improving treatment selection and resource allocation. This shift is influencing the diagnostic industry, where demand for genomic sequencing and companion diagnostic services continues to rise. For example, cancer centers are expanding molecular testing programs to identify patients eligible for targeted therapies. The transition is also encouraging pharmaceutical companies to focus research investments on genetically defined patient populations and rare oncology indications.
02

Transition from Rare Disease Underdiagnosis to Genomics Driven Identification

The market is also benefiting from a transition from limited rare disease recognition toward genomics-driven patient identification and disease classification. Advances in genetic testing technologies are enabling healthcare systems to detect rare cancers and hematologic disorders more effectively than in the past. This shift is creating growth opportunities across diagnostic laboratories, specialty healthcare providers, and precision medicine networks. For instance, broader adoption of genomic profiling is increasing referrals to specialized oncology and hematology centers where targeted treatments are available. As a result, the healthcare ecosystem is moving toward earlier diagnosis, more personalized treatment pathways, and stronger integration of molecular medicine into routine clinical practice.